MESOBLAST LIMITED

ASX: MSB

Sector: Sector:Health Care
Industry group: Industry:Pharmaceuticals, Biotechnology & Life Sciences

MSB News & Analysis

MSBHealth CareFinancial Results27 Aug 202627 August 2026· 2 min read

Mesoblast (ASX: MSB) Revenue Jumps to US$120.3 Million on Ryoncil Launch

Mesoblast’s Ryoncil launch lifted annual revenue to US$120.3 million and helped narrow its net loss. The company also completed treatment in a 350-patient Phase 3 back-pain trial.

Latest MSB ASX Announcements

1 Oct 2026 · 6:49 pmSubstantial Holders
Ceasing to be a substantial holder
1 Oct 20266:49 pmCeasing to be a substantial holderSubstantial Holders
30 Sept 2026 · 6:15 pmSubstantial Holders
Becoming a substantial holder
30 Sept 20266:15 pmBecoming a substantial holderSubstantial Holders
24 Sept 2026 · 9:52 amCompany Update
FDA Approves New Potency Assay for Commercial Ryoncil
24 Sept 20269:52 amFDA Approves New Potency Assay for Commercial RyoncilCompany Update
23 Sept 2026 · 6:41 pmSubstantial Holders
Ceasing to be a substantial holder
23 Sept 20266:41 pmCeasing to be a substantial holderSubstantial Holders
27 Aug 2026 · 8:39 amFinancial Results
MSB Annual Financial Results and Operational Update
27 Aug 20268:39 amMSB Annual Financial Results and Operational UpdateFinancial Results
27 Aug 2026 · 8:33 amFinancial Results
Annual Financial Results Presentation
27 Aug 20268:33 amAnnual Financial Results PresentationFinancial Results
27 Aug 2026 · 8:21 amFinancial Results
Preliminary Final Report including Appendix 4E
27 Aug 20268:21 amPreliminary Final Report including Appendix 4EFinancial Results
24 Aug 2026 · 5:50 pmDirector Interests
Appendix 3Y - Philip Krause
24 Aug 20265:50 pmAppendix 3Y - Philip KrauseDirector Interests
24 Aug 2026 · 5:40 pmSecurities Administration
Notification regarding unquoted securities - MSB
24 Aug 20265:40 pmNotification regarding unquoted securities - MSBSecurities Administration
24 Aug 2026 · 5:38 pmPresentations
Mesoblast 2026 Full Year Financial Results Webcast
24 Aug 20265:38 pmMesoblast 2026 Full Year Financial Results WebcastPresentations
17 Aug 2026 · 10:00 amCompany Update
Major Milestone Treatment Completed in P3 Trial for CLBP
17 Aug 202610:00 amMajor Milestone Treatment Completed in P3 Trial for CLBPCompany Update
13 Aug 2026 · 5:52 pmSubstantial Holders
Becoming a substantial holder
13 Aug 20265:52 pmBecoming a substantial holderSubstantial Holders
7 Aug 2026 · 5:02 pmSubstantial Holders
Ceasing to be a substantial holder
7 Aug 20265:02 pmCeasing to be a substantial holderSubstantial Holders
5 Aug 2026 · 6:29 pmSubstantial Holders
Becoming a substantial holder
5 Aug 20266:29 pmBecoming a substantial holderSubstantial Holders
3 Aug 2026 · 5:25 pmSubstantial Holders
Ceasing to be a substantial holder
3 Aug 20265:25 pmCeasing to be a substantial holderSubstantial Holders

View complete MSB announcement history →

MESOBLAST LIMITED

MSB Share Price

MSB News & Analysis

Mesoblast (ASX: MSB) Revenue Jumps to US$120.3 Million on Ryoncil Launch

Latest MSB ASX Announcements